Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE4450.3044.1 (+1 % )
PREV CLOSE (Rs.) 4406.20
OPEN PRICE (Rs.) 4452.30
BID PRICE (QTY) 4447.15 (11 )
OFFER PRICE (QTY) 4450.10 (50 )
VOLUME 22249
TODAY'S LOW / HIGH (Rs.)4427.20 4466.80
52 WK LOW / HIGH (Rs.)2497.6 5514.65
NSE4443.95 39.25 (+0.89 % )
PREV CLOSE(Rs.) 4404.70
OPEN PRICE (Rs.) 4465.00
BID PRICE (QTY) 4442.00 (11 )
OFFER PRICE (QTY) 4442.95 (1 )
VOLUME 323759
TODAY'S LOW / HIGH(Rs.) 4426.00 4468.40
52 WK LOW / HIGH (Rs.)2495.05 5512.65

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.56
TTM EPS (Rs.) 142.98
P/E Ratio 31.06
Book Value (Rs.) 979.36
Face Value (Rs.) 5
MCap (Rs. in Mn) 738415.21
Price/Earning (TTM) 23.12
Price/Sales (TTM) 5.79
Price/Book (MRQ) 4.53
PAT Margin (%) 24.79
ROCE (%) 18.58
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
01Mar03-01-2021$Dr.Reddys Laboratories informs about allotment of equity shares under ESOP Dr.Reddys Laboratories infor

Dr. Reddy's Laboratories has informed that the Nomination, Governance and Compensation Committee of the Board of Directors of the Company has allotted 2,253 equity shares of Rs 5 each of the Company, fully paid up, on March 1, 2021 to Employees on exercise of their Stock Options as per the following details: 1,116 equity shares of Rs 5 each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002 and 1,137 equity shares of Rs 5 each underlying 1,137 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007. Further, the company has enclosed the details as required under Regulation 10(c) of SEBI (Share Based Employee Benefits) Regulation, 2014.

The above information is a part of company’s filings submitted to BSE.

 

Dr. Reddy's Laboratories has informed that the Nomination, Gove..
22Feb02-22-2021$Dr. Reddy's Laboratories launches Lansoprazole DR Orally Disintegrating Tablets Dr. Reddy's Laboratories lau

Dr. Reddy's Laboratories along with its subsidiaries have launched Lansoprazole DR Orally Disintegrating Tablets a therapeutic equivalent generic version of Prevacid SoluTab Delayed Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).The Prevacid brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020.  The company’s Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories along with its subsidiaries have launc..
22Feb02-22-2021$Dr Reddys Laboratories informs about press release Dr Reddys Laboratories infor

Dr. Reddys Laboratories has informed that it has enclosed a Press Release on 22nd February 2021 titled ‘Dr. Reddy's Laboratories announces the launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Laboratories has informed that it has enclosed a Pre..
19Feb02-19-2021$Dr. Reddy's initiates process for Emergency Use Authorization of Sputnik V Dr. Reddy's initiates proces

Dr. Reddy's Laboratories has initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V.

As part of the review process, Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by February 21, 2021.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories has initiated the process with the Dru..
18Feb02-18-2021$Dr. Reddy's Laboratories launches Fluphenazine Hydrochloride Tablets Dr. Reddy's Laboratories lau

Dr. Reddy's Laboratories along with its subsidiaries have launched Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA). The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020. The company’s Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories along with its subsidiaries have launc..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit443729377
Gross Profit 6179 27758
Operating Profit 836836128
Net Sales 34082118504
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 14670.05 (1.02%)
M.Cap ( in Cr)
30989.13
Piramal Enterprises (BSE)
 1995.25 (4.03%)
M.Cap ( in Cr)
44234.82
Gland Pharma (BSE)
 2414.50 (2.75%)
M.Cap ( in Cr)
39365.24
Procter&Gamble Healt (BSE)
 6827.45 (0.87%)
M.Cap ( in Cr)
11289.90
Astrazeneca Pharma I (BSE)
 3514.50 (1.26%)
M.Cap ( in Cr)
8790.50
Shareholding Pattern More
NON-INSTITUTION 29.41 %
PROMOTERS 26.73 %
MUTUAL FUNDS/UTI 13.28 %
FI/BANKS/INSURANCE 1.05 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes